Vivli COVID-19 Portal

Ida Sim, MD, PhD
Vivli Co-Founder
Professor of Medicine, UCSF
April 24, 2020
Early peek at data on Gilead's drug suggests early survival benefit and positive outcome for COVID-19 patients

NIH clinical trial of therapy for COVID-19

Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study) (ConCoVid-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Balancing Risks and Benefits

Openness
Maximizing the value of the data collected respects participants' contributions

Privacy
Protecting participant privacy
Introducing Vivli

**THE ENTITY**
- Non-profit organization
- Convening function
  - Biomedical industry (pharma, bio, device)
  - Academia
  - Non-profit funders and foundations
  - Government (funders and regulators)
  - Patient/patient advocates
- Governance and policy
  - Harmonizing language & agreements
  - Move culture of data sharing
- Advocacy
  - Lowering barriers
  - Promoting incentives
- Oversight of Implementation

**THE PLATFORM**
- A user-friendly, secure, state-of-the-art data sharing and computing platform
- Serving the international community, including trials from any disease, country, sponsor, funder, or investigator
  - Open search
  - Robust security
  - Modern tools and technologies
Vivli by the numbers ...TODAY

- 5,000+ Trials
- 2.7M Participants from 111 countries
- 24 Members
Vivli Members
Secure Environment Bridges Multiple Platforms

Vivli Secure Environment

30+ packages
- STATA
- MS Office
- R
- Jupyter Notebook
- Python
- SAS

example Vivli partner data sources

BYO data, scripts, software on request
We are committed to advancing the knowledge around the COVID-19 pandemic
All fees are waived for sharing and accessing clinical trials
Share trials and find out more information >
Vivli’s COVID-19 Portal

- Provides a dedicated search function
- Availability of fast-tracked review and sharing
- Waiver of all fees to share, archive, access, and analyze COVID-19 trials
- Waiver of anonymization fees through key Vivli partners

“d-wise is proud to play its part to accelerate the sharing ecosystem in the fight against COVID-19.”

Stephen Baker, d-wise

Privacy Analytics will waive fees to anonymize COVID-19 vaccine and pivotal drug trials for a limited time to accelerate COVID-19 response*

*Data to be provided in specified SDTM format, waivers may be granted in exceptional cases
What is the process to share COVID-19 trials?

1. Sign Data Contributor Agreement
2. Provide NCT #
3. Provide protocol, data dictionary, statistical analysis plan
4. Vivli lists study on COVID-19 portal
5. Anonymization support
6. (Interim) Anonymized data uploaded
7. Study data available for request

(Updated) Anonymized data uploaded
Final study data available for request
What is the process to request COVID-19 trials?

1. Research team requests studies
2. Accelerated Research Proposal Check
3. Data Use Agreement executed
4. Access updated/final data
5. Research team accesses data and conducts analysis
6. Publication

Request closed

Revisions
Share Now, Pool IPD, Beat COVID-19!

Vivli enables data from multiple sources to be combined securely to more rapidly advance COVID-19 knowledge.

Given the urgency of the global pandemic, we will support sharing of some interim participant-level data followed by the final dataset.

Vivli available for sharing both observational and interventional studies.

Fee waiver and support for anonymization lowers barriers to sharing. Contact support@vivli.org.